It has been estimated that the cost of traffic accidents in Europe attributable to impairment from medications is 6.3 billion Euros each year. Thus, there is growing concern in the UK and the rest of Europe about the role of drugs and medicines in traffic accidents. There has been increasing attention afforded to medicinal drugs used to treat depression and comorbid disorders such as anxiety disorders including phobias, obsessive-compulsive disorders and panic disorders (Alvarez and Del Rio, 1994; Fairweather and Hindmarch,1995; Hale, 1994; Kerr and Hindmarch, 1995). Whereas there is already considerable evidence that old forms of treatment drug such as BZDs can impair driver functioning and increase accident risk, there is relatively less evidence for new forms of antidepressant drug such as SSRIs which are increasing in terms of prescription use. In view of this change in prescription patterns, it is necessary to review the effect of these drugs on driver impairment and accident risk. This report presents a systematic review of driving performance and accident risk in relation to antidepressant drugs based on relevant summary criteria for literature published after 1989. On the basis of this review, it is concluded that more research is required to investigate the effects of new generation antidepressant drugs on driving performance and accident risk. In this regard, the report concludes with recommendations for future research.